Jung D - Search Results

1

Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.

Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, Casserella S, Jung D. Cimoch PJ, et al. Among authors: jung d. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):227-34. doi: 10.1097/00042560-199803010-00007. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9495222 Clinical Trial.

2

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.

Jung D, Griffy K, Dorr A, Raschke R, Tarnowski TL, Hulse J, Kates RE. Jung D, et al. J Clin Pharmacol. 1998 Nov;38(11):1057-62. doi: 10.1177/009127009803801111. J Clin Pharmacol. 1998. PMID: 9824788 Clinical Trial.

3

Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.

Jung D, Griffy K, Dorr A. Jung D, et al. J Clin Pharmacol. 1999 Feb;39(2):161-5. doi: 10.1177/00912709922007714. J Clin Pharmacol. 1999. PMID: 11563408 Clinical Trial.

4

Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.

Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Anderson RD, et al. Among authors: jung d. Clin Ther. 1995 May-Jun;17(3):425-32. doi: 10.1016/0149-2918(95)80107-3. Clin Ther. 1995. PMID: 7585846 Clinical Trial.

5

Effect of food on the relative bioavailability of oral ganciclovir.

Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Connor J. Lavelle J, et al. Among authors: jung d. J Clin Pharmacol. 1996 Mar;36(3):238-41. doi: 10.1002/j.1552-4604.1996.tb04193.x. J Clin Pharmacol. 1996. PMID: 8690817 Clinical Trial.

6

Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients.

Wolfe EJ, Mathur V, Tomlanovich S, Jung D, Wong R, Griffy K, Aweeka FT. Wolfe EJ, et al. Among authors: jung d. Pharmacotherapy. 1997 May-Jun;17(3):591-8. Pharmacotherapy. 1997. PMID: 9165564 Clinical Trial.

7

Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus.

Jung D, Griffy K, Wong R, Colburn W, Hulse J. Jung D, et al. J Clin Pharmacol. 1998 Nov;38(11):1021-4. doi: 10.1177/009127009803801106. J Clin Pharmacol. 1998. PMID: 9824783 Clinical Trial.

8

The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients.

Jung D, AbdelHameed MH, Hunter J, Teitelbaum P, Dorr A, Griffy K. Jung D, et al. Br J Clin Pharmacol. 1999 Mar;47(3):255-9. doi: 10.1046/j.1365-2125.1999.00876.x. Br J Clin Pharmacol. 1999. PMID: 10215748 Free PMC article. Clinical Trial.

9

The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.

Jung D, AbdelHameed MH, Teitelbaum P, Dorr A, Griffy K. Jung D, et al. J Clin Pharmacol. 1999 May;39(5):505-12. J Clin Pharmacol. 1999. PMID: 10234599 Clinical Trial.

10

Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients.

Jung D, Griffy K, Wong R, Colburn W, Hulse J. Jung D, et al. J Clin Pharmacol. 1998 Dec;38(12):1122-8. J Clin Pharmacol. 1998. PMID: 11301564 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,238 results

Search Page